Bellevue Group AG Purchases New Stake in Neuronetics Inc (STIM)  Alanna Baker | Aug 17th, 2018
Bellevue Group AG purchased a new position in shares of Neuronetics Inc (NASDAQ:STIM) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $1,320,000.
Several other hedge funds also recently modified their holdings of the company. Peregrine Capital Management LLC bought a new stake in Neuronetics in the 2nd quarter worth about $4,659,000. Massachusetts Financial Services Co. MA purchased a new position in Neuronetics in the second quarter worth about $2,661,000. TD Asset Management Inc. purchased a new position in Neuronetics in the second quarter worth about $329,000. Emerald Mutual Fund Advisers Trust purchased a new position in Neuronetics in the second quarter worth about $1,570,000. Finally, Wells Fargo & Company MN purchased a new position in Neuronetics in the second quarter worth about $7,734,000. 13.20% of the stock is currently owned by institutional investors and hedge funds. Get Neuronetics alerts:
In related news, Director Wilfred E. Jaeger acquired 6,667 shares of the stock in a transaction dated Monday, July 2nd. The shares were purchased at an average cost of $17.00 per share, with a total value of $113,339.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link . Also, insider Daniel Guthrie acquired 1,500 shares of the stock in a transaction dated Monday, July 2nd. The shares were bought at an average cost of $17.00 per share, for a total transaction of $25,500.00. The disclosure for this purchase can be found here .
Shares of NASDAQ:STIM opened at $32.25 on Friday. Neuronetics Inc has a 52-week low of $23.95 and a 52-week high of $36.00.
Neuronetics (NASDAQ:STIM) last announced its earnings results on Tuesday, August 14th. The company reported ($30.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($29.76). The business had revenue of $13.25 million during the quarter, compared to analyst estimates of $12.20 million. research analysts predict that Neuronetics Inc will post -1.86 EPS for the current year.
Several research analysts have issued reports on the company. Canaccord Genuity raised their target price on Neuronetics from $33.00 to $36.00 and gave the stock a "buy" rating in a research report on Wednesday. BTIG Research reissued a "buy" rating and issued a $33.00 target price on shares of Neuronetics in a research report on Thursday. JMP Securities raised their target price on Neuronetics from $36.00 to $40.00 and gave the stock an "outperform" rating in a research report on Wednesday. Piper Jaffray Companies assumed coverage on Neuronetics in a research report on Monday, July 23rd. They issued an "overweight" rating on the stock. Finally, William Blair assumed coverage on Neuronetics in a research report on Monday, July 23rd. They issued an "outperform" rating on the stock. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of "Buy" and a consensus price target of $36.33.
Neuronetics Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Featured Story: NASDAQ
Want to see what other hedge funds are holding STIM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neuronetics Inc (NASDAQ:STIM). Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter . Ã‚